4521 On Other Exchanges
Symbol
Exchange
4521 is not on other exchanges.

kaken pharmaceutical co ltd (4521) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAKEN PHARMACEUTICAL CO LTD (4521)

Related News

No related news articles were found.

kaken pharmaceutical co ltd (4521) Related Businessweek News

No Related Businessweek News Found

kaken pharmaceutical co ltd (4521) Details

Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. It operates through Pharmaceuticals and Real Estate segments. The company offers pharmaceutical products and medical devices, such as Artz, an anti-osteoarthritis drug to treat knee joint pain accompanied by rheumatoid arthritis; Clenafin, a triazole compound for topical medication of onychomycosis; Seprafilm, an anti-adhesive absorbent barrier; Lipidil, an anti-hyperlipidemia product; and Fiblast Spray, a wound-healing drug. Its pharmaceutical products and medical devices also include Procylin, which is used to treat chronic artery occlusive diseases and pulmonary hypertension; Adofeed, a pain- and inflammation-relieving plaster; Mentax, a topical product used to treat superficial mycosis; Ebrantil, an a1 blocker to treat dysuria and hypertension; Berasus to treat pulmonary arterial hypertension; and Clexane, an anticoagulant for the treatment of patients who undergo podiatric or abdominal surgery, as well as generic drugs. In addition, the company provides agrochemicals, including Polyoxins that is used as fungicide; and Pentoxazone, a rice herbicide. Further, it offers animal health products comprising Salinomycin, an anti-coccidial feed additive for chicken; and Colistin sulfate, a polypeptide antibiotic effective against gram-negative bacteria. Additionally, the company is developing KCB-1D for the treatment of periodontitis; KAG-308, a Phase II clinical product to treat ulcerative colitis; and BBI-4000 that is preparing for Phase II to treat primary focal hyperhidrosis. It focuses on fields, such as inflammation, allergies, and pain relief, as well as fungal infection. The company also rents Bunkyo Green Court commercial facility. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

1,451 Employees
Last Reported Date: 06/29/16
Founded in 1917

kaken pharmaceutical co ltd (4521) Top Compensated Officers

President and Representative Director
Total Annual Compensation: ¥110.0M
Compensation as of Fiscal Year 2016.
kaken pharmaceutical co ltd
Kaken Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the Third Quarter of Fiscal 2016

Kaken Pharmaceutical Co., Ltd. announced consolidated earnings results for the third quarter of fiscal 2016. For the quarter, the company reported net sales of ¥85,431 million against ¥78,965 million a year ago. Operating income was ¥29,689 million against ¥24,953 million a year ago. Ordinary income was ¥29,919 million against ¥25,232 million a year ago. Net income was ¥20,134 million against ¥17,983 million a year ago.

Kaken Pharmaceutical Co., Ltd. to Report Q3, 2017 Results on Feb 06, 2017

Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2017 results on Feb 06, 2017

Kaken Pharmaceutical Co. Ltd. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2016; Provides Consolidated Earnings Guidance for the Fiscal 2016

Kaken Pharmaceutical Co. Ltd. announced consolidated earnings results for the six months ended September 30, 2016. On consolidated basis, the company’s net sales were JPY 52,179 million against JPY 54,973 million a year ago. Operating income was JPY 16,123 million against JPY 18,443 million a year ago. Ordinary income was JPY 16,238 million against JPY 18,573 million a year ago. Net income was JPY 11,446 million against JPY 12,483 million a year ago. Net income per basic share was JPY 278.02 against JPY 301.39 a year ago. Net cash provided by operating activities was JPY 5,699 million against JPY 10,551 million a year ago. The company provided consolidated earnings guidance for the fiscal 2016. For the year, the company expects net sales of JPY 106,100 million, operating income of JPY 28,900 million, ordinary income of JPY 29,100 million, net income of JPY 20,800 million and net income per basic share of JPY 508.90.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4521 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4521.
View Industry Companies
 

Industry Analysis

4521

Industry Average

Valuation 4521 Industry Range
Price/Earnings 13.6x
Price/Sales 2.5x
Price/Book 2.6x
Price/Cash Flow 15.7x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KAKEN PHARMACEUTICAL CO LTD, please visit www.kaken.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.